Insider Trading Activity Argos Therapeutics Inc (NASDAQ:ARGS) – CEO Sold 114,702 shares of Stock

ME Staff
-
0

Insider Trading Activity For Argos Therapeutics Inc (NASDAQ:ARGS)

Jeffrey D Abbey , CEO of Argos Therapeutics Inc (NASDAQ:ARGS) reportedly Sold 114,702 shares of the company’s stock at an average price of 0.16 for a total transaction amount of $18,352.32 SEC Form

Insider Trading History For Argos Therapeutics Inc (NASDAQ:ARGS)

  • On 2/12/2014 International S Pharmstandard, Major Shareholder, bought 1,275,000 with an average share price of $8.00 per share and the total transaction amounting to $10,200,000.00.View SEC Filing
  • On 2/12/2014 Deventer Sander Van, Director, bought 36,416 with an average share price of $8.00 per share and the total transaction amounting to $291,328.00.View SEC Filing
  • On 8/19/2015 Jeffrey D Abbey, CEO, bought 5,500 with an average share price of $4.75 per share and the total transaction amounting to $26,125.00.View SEC Filing
  • On 8/25/2015 Jean Lamarre, Director, bought 2,500 with an average share price of $6.14 per share and the total transaction amounting to $15,350.00.View SEC Filing
  • On 9/1/2015 Holle Philippe Marie Marce Van, Director, bought 5,000 with an average share price of $6.26 per share and the total transaction amounting to $31,300.00.View SEC Filing
  • On 9/3/2015 Holle Philippe Marie Marce Van, Director, bought 12,000 with an average share price of $6.27 per share and the total transaction amounting to $75,240.00.View SEC Filing
  • On 11/24/2015 Holle Philippe Marie Marce Van, Director, bought 10,000 with an average share price of $4.28 per share and the total transaction amounting to $42,800.00.View SEC Filing

    • Analyst Ratings History For Argos Therapeutics Inc (NASDAQ:ARGS)

    • On 3/9/2016 JPMorgan Chase & Co. Lower Price Target of rating Market Outperform with a price target of $17.00 to $12.00
    • On 4/19/2016 Roth Capital Boost Price Target of rating Buy with a price target of $11.00 to $18.00
    • On 6/20/2016 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $11.00
    • On 2/22/2017 JMP Securities Downgraded rating Outperform to Market Perform
    • On 2/22/2017 Needham & Company LLC Downgraded rating Buy to Hold
    • On 3/17/2017 Stifel Nicolaus Lower Price Target of rating Hold with a price target of $1.20
    • On 4/19/2017 FBR & Co Lower Price Target of rating Mkt Perform to Mkt Perform with a price target of $2.00 to $1.20

    Recent Trading Activity for Argos Therapeutics Inc (NASDAQ:ARGS)
    Shares of Argos Therapeutics Inc closed the previous trading session at 0.16 down -0.01 5.33% with 4443631 shares trading hands.